Skip to main content

Stalfort John A III's Form 4 filing

Taysha Gene Therapies, Inc.TSHA · filed Aug 16, 2023

Accession no.
0001209191-23-046152
Filed
Aug 16, 2023
Trade date
Aug 16, 2023
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market purchases total $700.0K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Stalfort John A IIICIK 0001709418Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 16, 2023Common StockPPurchaseAcquired+388,889$0.90+$350,000.1884,290Indirect
Aug 16, 2023Common StockPPurchaseAcquired+388,889$0.90+$350,000.1999,381Direct
Aug 16, 2023Common StockGGiftAcquired+50,000$0.00$01,049,381Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)